← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Combinations of antineoplastic agents
bifikafusp alfa and onfekafusp alfa
L01XY04
Forms & Strengths
- bifikafusp alfa and onfekafusp alfa injection: 25 mg/25 mg per 1 mL
- single-dose vial
Adult Dosing
- 900 mg/900 mg IV on day 1, 600 mg/600 mg IV on day 8, and 600 mg/600 mg IV on day 15 of a 21-day cycle
- administer as an intravenous infusion over 30 minutes
Pediatric Dosing
- safety and efficacy not established in pediatric patients
Indications
- treatment of adult patients with locally advanced or metastatic urothelial carcinoma
- who are not eligible for cisplatin-containing chemotherapy
Mechanism of Action
- bifikafusp alfa: anti-PD-1 antibody to block PD-1/PD-L1 interaction
- onfekafusp alfa: anti-CTLA-4 antibody to block CTLA-4/B7 interaction
- enhances T-cell activation and proliferation
Adverse Reactions
- anemia
- fatigue
- decreased appetite
- rash
- pruritus
- diarrhea
- nausea
- vomiting
- infusion-related reactions
- immune-mediated adverse reactions
Drug Interactions
- concomitant use with immunosuppressants may decrease efficacy
- avoid live vaccines during treatment
Curated Content: Needs Vetting Before Put to Clinical Use